Chris O'Brien Lifehouse

RedHill and Bayer Launch Phase 2 Trial Combining Opaganib with Darolutamide for Advanced Prostate Cancer

4 months ago

• RedHill Biopharma initiates an 80-patient Phase 2 study testing opaganib in combination with Bayer's darolutamide for metastatic castrate-resistant prostate cancer, with financial backing from Bayer and Ramsay Hospital Research Foundation. • The study will utilize a novel PCPro biomarker test to identify patients with poor prognosis who may benefit from the combination therapy, with the primary endpoint being 12-month radiographic progression-free survival. • Prostate cancer affects approximately 1.5 million new patients annually worldwide, with the study targeting a significant unmet need in the $12 billion market for patients who develop resistance to standard treatments.